Beam Inc. News - BEAM

BMO Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

BMO Capital analyst Kostas Biliouris maintained a Hold rating on Beam Therapeutics (BEAM - Research Report) today and set a price target of...

Wall Street Analysts Are Neutral on Top Healthcare Picks

Analysts fell to the sidelines weighing in on Amgen (AMGN – Research Report) and Beam Therapeutics (BEAM – Research Report) with neutral ratings...

U.S. FDA Removes Clinical Hold For BEAM Drug Candidate

Shares of Beam Therapeutics Inc. (NASDAQ: BEAM) were down in morning trading on Friday even as the biotechnology company announced that the U.S...

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

In a report released on November 7, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM - Research Report), with a price...

Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital

RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on May 9 and set a price target of $85.00...

Barclays Keeps a Hold Rating on Beam Therapeutics (BEAM)

Barclays analyst Gena Wang maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on May 9 and set a price target of $38.00. The...

Beam Therapeutics (BEAM) Receives a Hold from J.P. Morgan

In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price...

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACAD – Research Report...

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Barclays analyst Gena Wang maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on February 28 and set a price target of $80.00...

Wells Fargo Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

In a report issued on January 7, Yanan Zhu from Wells Fargo maintained a Buy rating on Beam Therapeutics (BEAM – Research Report). The company's...

William Blair Keeps a Buy Rating on Beam Therapeutics (BEAM)

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Beam Therapeutics (BEAM – Research Report). The company's...

Understanding Beam Therapeutics’ Risk Factors Post Q2

Shares of biotechnology company Beam Therapeutics (BEAM) have climbed almost 8% since the company reported its second-quarter results on August...

Apellis’ Pipeline Creating Attractive Entry Point, Analyst Says

preclinical programs across nephrology, neurology, hematology, and ophthalmology indications.https://www.tipranks.com/news/article/apellis-pipeline...

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

OMB APPROVAL OMB Number: 3235-0167 Expires: &n...

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

OMB APPROVAL OMB Number: 3235-0167 Expires: &n...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Beam Inc. (BEAM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BEAM News

BMO Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

Wall Street Analysts Are Neutral on Top Healthcare Picks

U.S. FDA Removes Clinical Hold For BEAM Drug Candidate

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital

Barclays Keeps a Hold Rating on Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) Receives a Hold from J.P. Morgan

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Wells Fargo Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

William Blair Keeps a Buy Rating on Beam Therapeutics (BEAM)

Understanding Beam Therapeutics’ Risk Factors Post Q2

Apellis’ Pipeline Creating Attractive Entry Point, Analyst Says

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

BEAM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Beam Inc. (BEAM) News

Beam Inc. (BEAM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BEAM News

BMO Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

Wall Street Analysts Are Neutral on Top Healthcare Picks

U.S. FDA Removes Clinical Hold For BEAM Drug Candidate

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital

Barclays Keeps a Hold Rating on Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) Receives a Hold from J.P. Morgan

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)

Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Wells Fargo Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

William Blair Keeps a Buy Rating on Beam Therapeutics (BEAM)

Understanding Beam Therapeutics’ Risk Factors Post Q2

Apellis’ Pipeline Creating Attractive Entry Point, Analyst Says

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

BEAM Discussion

Your Recent History